Neurocrine Biosciences
NBIX
#1451
Rank
C$16.84 B
Marketcap
$166.37
Share price
-3.89%
Change (1 day)
8.06%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2023 (TTM): $2.63

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is $2.76. In 2022 the company made an earnings per share (EPS) of $2.27 an increase over its 2021 EPS that were of $1.34.

EPS history for Neurocrine Biosciences from 1997 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$2.6316.12%
2022$2.2769.47%
2021$1.34-78.21%
2020$6.14990%
2019$0.5681.82%
2018$0.31-113.5%
2017-$2.300.62%
2016-$2.2857.28%
2015-$1.4525.61%
2014-$1.1618.84%
2013-$0.97-1085.71%
2012$0.09862-89.71%
2011$0.96-500%
2010-$0.24-86.92%
2009-$1.83-43.48%
2008-$3.24-57.8%
2007-$7.6892.58%
2006-$3.99371.67%
2005-$0.85-52.76%
2004-$1.7936.56%
2003-$1.31-70%
2002-$4.37118.31%
2001-$2.008.4%
2000-$1.8548.86%
1999-$1.24-20%
1998-$1.55-479.31%
1997$0.41

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$2.94 6.63%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.77-71.94%๐Ÿ‡ฌ๐Ÿ‡ง UK
-$4.17-251.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$7.65 177.00%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.19 87.79%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.62-5.10%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.66-123.98%๐Ÿ‡บ๐Ÿ‡ธ USA
-$4.27-254.59%๐Ÿ‡บ๐Ÿ‡ธ USA